Skip to main content
Displaying 1 - 12 of 29
Display:
12
24
48
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Immune-Mediated and Cholestatic Diseases
4
Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Pagination
Current page
1
Page
2
Page
3
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy